Tardive Dyskinesia

Welcome to the survey activity

Teva recently conducted a research survey among the general population in the United States to estimate the impact of tardive dyskinesia (TD) on quality of life.

The survey asked them questions to determine how many years with TD, with or without a mental health disorder, they were willing to give up to live in full health. The responses from the survey were used to calculate utility values, which are used to help assess the burden of TD. Limited data exists on the quality of life and social consequences of TD, which may lead to underestimating the value of TD treatment. Our aim was to increase understanding of the condition and highlight what it would be like to live with TD.

In this short activity, you will be shown a scenario and then asked a series of questions based on the survey. You can then see how people who took the survey responded and also view the poster with the survey results. You can view the poster at any time by clicking the link at the top of
the screen. 

Please select a scenario and press continue.
Or click on the random scenario generator and one will be selected for you.

Scenario 1 Living with TD
Scenario 2 Schizophrenia with negative symptoms and TD
Scenario 3 Schizophrenia with positive symptoms and TD
Scenario 4 Bipolar disorder and TD
Scenario 5 Major depressive disorder and TD

Utility values

Close

Utilities are values that reflect an individual’s preferences for different health outcomes and reflect societal perceived disease severity. They are typically measured on a scale, with zero reflecting states of health equivalent to death and one reflecting perfect health. They are used by decision-makers to more accurately assess treatment benefit.

References: What_are_health_util.pdf (bandolier.org.uk) 2021 American Academy of Neurology Abstract Website (mirasmart.com) (Claassen et al AAN 2021)

TD References

Close

Primary References

WPA 2021 TD Utility poster

Additional References
1. Waln O, Jankovic J. Tremor Other Hyperkinet Mov (N Y). 2013;3:1-11.
2. Boumans CE, et al. Schizophr Bull. 1994;20(2):339-344.
3. Ayyagari R, et al. CNS Spectr. 2020;25(2):275-276.
4. Bleichrodt H. Health Econ. 2002;11(5):447-456.
5. van Osch SMC, et al. Med Decis Making. 2004;24(5):511-517.
6. Wright DR, et al. Pharmacoeconomics. 2009;27(9):713-723.
7. Bleichrodt H, Johannesson M. J Health Econ. 1997;16(2):155-175.
8. What_are_health_util.pdf (bandolier.org.uk)
9. 2021 American Academy of Neurology Abstract Website (mirasmart.com) (Claassen et al AAN 2021)